BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

DEA Suspends a Cardinal Health, Inc. (CAH) Substance-Control License


11/30/2007 12:15:07 AM

DUBLIN, Ohio, Nov. 29 /PRNewswire-FirstCall/ -- Cardinal Health today announced that the U.S. Drug Enforcement Administration (DEA) will temporarily suspend its license to distribute controlled substances from its Auburn, Wash. distribution center effective Dec. 3.

The company said the suspension affects only the Washington facility and only controlled substance shipments from that facility. Steps are being taken to ensure continuity of service to its customers.

In an order received today, the DEA said Cardinal Health "failed to maintain effective controls against the diversion of a particular controlled substance," and cites the sale of hydrocodone to one pharmacy that allegedly dispensed excessive amounts of the drug based on illegitimate prescriptions from Internet pharmacy web sites.

Cardinal Health said the security of the pharmaceutical supply chain is among its highest priorities, and it will cooperate fully with the DEA to resolve the suspension.

About Cardinal Health

Headquartered in Dublin, Ohio, Cardinal Health, Inc. is an $87 billion, global company serving the health care industry with products and services that help hospitals, physician offices and pharmacies reduce costs, improve safety, productivity and profitability, and deliver better care to patients. With a focus on making supply chains more efficient, reducing hospital-acquired infections and breaking the cycle of harmful medication errors, Cardinal Health develops market leading technologies, including Alaris(R) IV pumps, Pyxis(R) automated dispensing systems, MedMined(TM) infection surveillance services and the CareFusion(TM) patient identification system. The company also manufactures medical and surgical products and is one of the largest distributors of pharmaceuticals and medical supplies worldwide. Ranked No. 19 on the Fortune 500 and No. 1 in its sector on Fortune's ranking of Most Admired firms, Cardinal Health employs more than 40,000 people on five continents. More information about the company may be found at http://www.cardinalhealth.com.

CONTACT: Jim Mazzola, +1-614-757-3690, jim.mazzola@cardinal.com;
Investors: Bob Reflogal, +1-614-757-7542, bob.reflogal@cardinal.com, both
of Cardinal Health, Inc.

Web site: http://www.cardinalhealth.com/



Read at BioSpace.com
Read at Reuters

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES